Carlsmed, Inc. Common Stock (CARL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Carlsmed, Inc. Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 12.60 $ — 46% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 47.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.47 | -1.58 – -1.35 | 75 | 25.5% | 2 |
| 12/31/2027 | -1.44 | -1.63 – -1.24 | 105 | 2.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.40 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.17 | – | 9 | 117.00 | -50.20 | -4 | -4 |
| 2025: Q1 | -0.21 | – | 10 | 100.30 | -56.20 | -8 | -8 |
| 2025: Q2 | -0.25 | – | 12 | 98.70 | -56.00 | -7 | -8 |
| 2025: Q3 | -0.31 | – | 13 | 98.40 | -65.20 | -9 | -9 |
| 2025: Q4 | -0.34 | – | 15 | 61.20 | -60.60 | -5 | -5 |
| 2026: Q1 | -0.32 | – | 16 | 58.20 | -54.00 | -13 | -13 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2023 | 14 | -19 | -19 | -4.25 | -17 | -46 | 14 |
| 2024 | 27 | -24 | -24 | -1.46 | -25 | -71 | 52 |
| 2025 | 51 | -31 | -30 | -2.12 | -29 | 99 | 130 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Carlsmed, Inc., ein Medizintechnikunternehmen in der Vermarktungsphase, entwirft, fertigt und vermarktet KI-gestützte, personalisierte Lösungen für die Wirbelsäulenchirurgie.
| Employees | 127 |
|---|---|
| Headquarters | Carlsbad, CA |
| Address | 1800 Aston Avenue, 92008 Carlsbad, United States |
| Phone | 760 766 1923 |
| Website | carlsmed.com |
| IPO Date | 23. Jul 2025 |
| ISIN | US14280C1053 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael John Cordonnier | Co-Founder, Chairman, CEO & President | 1977 |
| Niall Patrick Casey J.D. | Co-Founder, Chief Intellectual Property Officer & Director | 1977 |
| Leonard M. Greenstein J.D. | CFO & Treasurer | 1976 |
| William Durall | Chief Commercial Officer | 1964 |
| Shariq Hussain | Chief Technology Officer | – |
| Stephanie Zhadkevich | VP & Head of Investor Relations | – |
| Jenifer Kamocsay | Chief Legal Officer & Secretary | – |
| Jodi Allen Coe M.B.A. | Senior Vice President of People & Culture | – |
| Sharon V. Schulzki | Chief Clinical & Market Access Officer | 1958 |
| Jeff Bertolini | Senior Vice President of Operational Excellence | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.